Trials / Completed
CompletedNCT00685698
Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections
An Open-Label, Single-Arm, Multi-Center Study of TG-873870 for Treating Patients With Diabetic Foot Infections of Mild to Moderate Severity Associated With Gram-Positive Pathogens
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- TaiGen Biotechnology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections
Detailed description
This study will assess the safety and efficacy of TG-873870 (Nemonoxacin) in patients with Diabetic Foot Infections. Pharmacokinetic (PK) and pharmacodynamic (PD) assessment will be conducted in a subgroup of eight consenting patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TG-873870 (Nemonoxacin) | 750 mg |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2009-04-01
- Completion
- 2009-06-01
- First posted
- 2008-05-28
- Last updated
- 2025-07-01
- Results posted
- 2015-01-09
Locations
16 sites across 4 countries: United States, South Africa, Taiwan, Thailand
Source: ClinicalTrials.gov record NCT00685698. Inclusion in this directory is not an endorsement.